New nonmetastatic PCa agents address unmet need
|
Three novel androgen receptor inhibitors provide an embarrassment of riches when it comes to treatment options for nmCRPC patients, but there are still questions to be answered—including the extent of these drugs’ clinical benefit. |
Learn more
|